Optimer Pharmaceuticals (Nasdaq: OPTR) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Optimer Pharmaceuticals beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share dropped.
Margins increased across the board.
Revenue details
Optimer Pharmaceuticals recorded revenue of $49.8 million. The 11 analysts polled by S&P Capital IQ hoped for a top line of $44.6 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at -$0.01. The 11 earnings estimates compiled by S&P Capital IQ predicted -$0.05 per share. GAAP EPS were -$0.01 for Q2 against -$0.52 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 91.9%, 3,174,510 basis points better than the prior-year quarter. Operating margin was 0.7%, 7,515,300 basis points better than the prior-year quarter. Net margin was -0.6%, 7,281,060 basis points better than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $26.6 million. On the bottom line, the average EPS estimate is -$0.44.
Next year's average estimate for revenue is $111.8 million. The average EPS estimate is -$1.21.
Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 112 members out of 147 rating the stock outperform, and 35 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Optimer Pharmaceuticals a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is buy, with an average price target of $19.50.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Optimer Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Optimer Pharmaceuticals to My Watchlist.
